A Phase 1, Multinational Study of MCLA-117 in Acute Myelogenous Leukemia
The goal of this clinical research study is to find the highest tolerable dose of MCLA-117 that can be given to patients with acute myeloid leukemia (AML). Researchers also want to learn about the safety and effects of the drug. This is the first study using MCLA-117 in humans.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: MCLA-117
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: Merus N.V.
IRB Review and Approval Date: 08/08/2018
Recruitment Status: Open
Projected Accrual: 50
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: